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Role of Endothelial Nitric Oxide Synthase
in Isoflurane Conditioning-Induced
Neurovascular Protection in Subarachnoid
Hemorrhage
Umeshkumar Athiraman
Gregory J. Zipfel, MD

, MD; Keshav Jayaraman, BA; Meizi Liu, MD; Tusar Giri, MD, PhD; Jane Yuan

, BA;

BACKGROUND: Delayed cerebral ischemia remains a common and profound risk factor for poor outcome after subarachnoid
hemorrhage (SAH). The aim of our current study is to define the role of endothelial nitric oxide synthase (eNOS) in isoflurane
conditioning-induced neurovascular protection after SAH.
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METHODS AND RESULTS: Ten- to 14-week-old male wild-type mice (C57BL/6) as controls and eNOS knockout male mice
(strain # 002684) were obtained for the study. Animals underwent either sham surgery, SAH surgery, or SAH with isoflurane
conditioning. Anesthetic post conditioning was performed with isoflurane 2% for 1 hour, 1 hour after SAH. Normothermia
was maintained with the homeothermic blanket. In a separate cohort, nitric oxide synthase was inhibited by a pan nitric oxide
synthase inhibitor, L-nitroarginine methyl ester. Vasospasm measurement was assessed 72 hours after SAH and neurological function was assessed daily. Isoflurane-induced changes in the eNOS protein expression were measured. eNOS protein
expression was significantly increased by isoflurane conditioning in naïve mice as well as mice subjected to SAH. Vasospasm
of the middle cerebral artery and neurological deficits were evident following SAH versus sham surgery, both in wild-type mice
and eNOS knockout mice. Isoflurane conditioning attenuated vasospasm and neurological deficits in wild-type mice. This
delayed cerebral ischemia protection was lost in L-nitroarginine methyl ester -administered mice and eNOS knockout mice.
CONCLUSIONS: Our data indicate isoflurane conditioning provides robust protection against SAH-induced vasospasm and neurological deficits, and that this delayed cerebral ischemia protection is critically mediated via isoflurane-induced augmentation
of eNOS.
Key Words: aneurysmal subarachnoid hemorrhage ■ delayed cerebral ischemia ■ endothelial nitric oxide synthase

■ isoflurane conditioning

D

espite an improved understanding of vasospasm
pathophysiology and advances in medical and
endovascular techniques for rescue therapy,
cerebral vasospasm and the delayed cerebral ischemia (DCI) that it produces remains a common and
profound risk factor for poor outcome after aneurysmal subarachnoid hemorrhage (SAH).1 Though many
strategies to prevent DCI have been explored over
the years, none have proven efficacious. This is likely

attributable to targeting individual elements of what
has proven to be a multifactorial process. Conditioning
is a therapeutic strategy that leverages endogenous
protective mechanisms to exert powerful and remarkably pleiotropic protective effects against injury to all
major cell types of the central nervous system including neurons, glia, and vascular cells.2 We previously
showed that structurally distinct conditioning agents
(hypoxia3 and the inhalational anesthetic, isoflurane4)
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CLINICAL PERSPECTIVE
What Is New?

• We examined the role of isoflurane conditioning
and the endothelial nitric oxide synthase (eNOS)
pathway in subarachnoid hemorrhage (SAH), a
pathophysiologically unique and more severe
form of stroke, that has not been previously
examined.
• Our data suggests that isoflurane conditioning provides strong protection against SAHinduced delayed cerebral ischemia and that this
protection is causally mediated through eNOS.

What Are the Clinical Implications?

• Our findings lend biological relevance to the observation that isoflurane conditioning provides
robust neurovascular protection in the setting of
SAH, and has significant translational potential
given that isoflurane is already approved by the
FDA for use in patients.

Nonstandard Abbreviations and Acronyms
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DCI
eNOS
L-NAME

delayed cerebral ischemia
endothelial nitric oxide synthase
L-nitroarginine methyl ester

provide strong protection against SAH-induced DCI in
mice endovascular perforation model. In the case of
hypoxic conditioning, endothelial nitic oxide synthase
(eNOS) was implicated in the afforded DCI protection.3
In the case of isoflurane conditioning, previous investigators have demonstrated that eNOS is likely a key
downstream effector for the anesthetic-based organ
protection,5 though none have examined its impact on
SAH-induced brain injury. The aim of our current study
is to evaluate the role of eNOS in isoflurane-induced
protection against vasospasm and neurological deficits following SAH. Our hypothesis is that isoflurane
conditioning induces robust protection against DCI
after SAH, and that eNOS is the key molecular inducer
of this neurovascular protection.

METHODS
The data that support the findings of this study are
available from the corresponding author on reasonable
request. All studies were approved by the animal studies committee at Washington University in Saint Louis.
Ten- to 14-week-old male wild-type mice (C57BL/6J)

as controls and eNOS knockout male mice (strain #
002684, B6.129P2-Nos3tm1Unc/J with C57BL/6J
genetic background) were obtained from Jackson
Laboratories (Bar Harbor, ME). Animals underwent
either sham surgery, SAH surgery or SAH with isoflurane conditioning. SAH was induced by endovascular
perforation model as explained previously.4 Briefly, a
5-0 blunted nylon suture was advanced through left
external carotid artery into internal carotid artery and
advanced distally until the resistance is felt at its bifurcation into anterior cerebral artery and middle cerebral
artery. The suture was advanced to cause perforation
in the SAH group and the suture was removed without
perforation in the sham group. Anesthetic conditioning
was performed with isoflurane 2% for 1 hour beginning
1 hour after induction of SAH. Briefly, spontaneously
breathing mice were placed in the anesthetic induction
chamber and perfused with isoflurane 2% with room
air for 1 hour. The sham group were placed in the same
induction chamber but exposed only to room air for
1 hour. Isoflurane concentration in the anesthetic induction chamber was measured by an anesthetic gas
analyzer. (Datex Ohmeda, Capnomac Ultima, USA)
Normothermia at 37°C was maintained with the homeothermic blanket. To examine the role of nitric oxide
synthase (NOS) in isoflurane conditioning induced neurovascular protection, a separate wild-type cohort was
injected with pan NOS inhibitor, L-nitroarginine methyl
ester (L-NAME) 20 mg/kg intraperitoneally 1 hour before SAH induction and every day thereafter until the
animal was euthanized. SAH -induced large artery
vasospasm was measured at 72 hours after SAH by
a pressure controlled cerebrovascular casting with
ROX-SE (5-(and-6)-Carboxy-X-rhodamine, succinimidyl ester) technique.6 The narrowest diameter within
the first 1000 um in the middle cerebral artery vessel
was measured to evaluate for vasospasm using a fluorescent microscope using a charged-coupled device
(CCD) camera (Cool SNAP EZ, Photometrics, Tucson,
AZ) and MetaMorph software (Universal Imaging, West
Chester, PA). Neurological outcome was measured at
baseline and for the next 3 days as explained previously.3,4 Briefly, it was measured by a motor score
(0–12) that evaluated spontaneous activity, symmetry
of limb movements, climbing, balance, and coordination and sensory score (4–12) that evaluated body
proprioception, vibrissae, visual and tactile response.
All experiments were randomized and blinded such
that the investigator assessing the neurological outcome and vasospasm is blinded to the treatment
group. Isoflurane-induced changes in the eNOS protein expression with and without SAH were measured
via Western blot technique as explained previously.3
Briefly, brains harvested at different time points after
isoflurane exposure with and without SAH surgery
were lysed in a radioimmunoprecipitation assay buffer

J Am Heart Assoc. 2020;9:e017477. DOI: 10.1161/JAHA.120.0174772

Athiraman et al

containing protease/phosphatase inhibitor cocktail.
Equal amounts of protein (30 μg) were loaded and separated by 10% to 15% SDS-PAGE gel electrophoresis
and then transferred to polyvinylidene difluoride membrane. The membrane was blocked by 5% milk in 1X
Tris-Buffered Saline, 0.1% Tween detergent for 1 hour
at room temperature and was incubated overnight at
4°C with rabbit anti-eNOS primary antibody (1:1000,
Cell signaling Technology) and rabbit anti-B actin antibody (1:1000, Cell signaling Technology) in 5% bovine
serum albumin. Subsequently, the blot was incubated
with anti-rabbit horseradish peroxidase-conjugated
secondary antibody (1:1000, Cell Signaling technology)
at room temperature for 1 hour. The protein bands were
visualized using an enhanced chemiluminescence kit
(BioRad) and quantified by ImageJ.

Isoflurane Conditioning and eNOS in SAH

Isoflurane Conditioning Attenuates
Vasospasm and Improves Neurological
Outcome After SAH in Wild-Type Mice
Out of a total of 78 wild-type mice used in the experiment, 4 animals (5%) died in SAH group and none died
A

Statistical Analysis
Data are represented as the mean±SEM. Large artery
vasospasm and neurological outcome were analyzed
by ANOVA and 2-way repeated measures ANOVA followed by Newman Keuls multiple comparison test.
Western blot data were analyzed by a t test and
ANOVA followed by Newman Keuls multiple comparison test. Statistical significance was set at P<0.05.

B
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RESULTS
eNOS Protein Expression After Isoflurane
Conditioning With and Without SAH
eNOS protein expression was measured at different
time points after single time exposure to 2% isoflurane
for 1 hour. Isoflurane exposure significantly increased
eNOS protein expression at 12, 36, 48, and 72 hours
(P<0.05) (Figure 1A and 1B). In a separate cohort of
mice that underwent SAH followed by isoflurane conditioning (isoflurane 2% for 1 hour, 1 hour after SAH),
eNOS protein expression was significantly increased
24 hours after SAH (P<0.05, Figure 1C).

C

Figure 1. Isoflurane and endothelial nitric oxide synthase
protein expression with and without SAH.
A, Wild-type mice were exposed to air or 2% isoflurane for 1 hour
and cortical tissue harvested immediately and at 12, 36, 48, and
72 hours after isoflurane exposure were subjected to Western
blot. Data indicate mean±SEM. *P<0.05, **P<0.01 vs control
(no isoflurane) by t test, n=4 mice per group. B, Representative
immunoblot images. C, Wild-type mice underwent sham or SAH
surgery and exposed to isoflurane 2% for 1 hour after 1-hour
post-SAH. Cortical tissue harvested at 24 hours post-surgery
were subjected to Western blot. Data indicate mean±SEM.
*P<0.05 sham vs SAH-post-conditioning, *P<0.05 SAH vs
SAH-post-conditioning by ANOVA followed by Newman-Keuls
multiple comparison test (sham, n=9; SAH, n=9; SAH+Isoflurane,
n=14). eNOS indicates endothelial nitric oxide synthase; postC,
post-conditioning; and SAH, subarachnoid hemorrhage.
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B
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C

Figure 2. Isoflurane conditioning attenuates SAH-induced vasospasm in wild-type mice.
A, Mice underwent sham or SAH surgery and exposed to isoflurane 2% for 1 hour after 1-hour
post-SAH. On post-surgery day 3, mice were perfused with ROX-SE staining and vessel diameter
in the proximal middle cerebral artery ipsilateral to suture perforation was measured. Data indicate
mean±SEM. B, Representative images of 5-(and-6)-Carboxy-X-rhodamine, succinimidyl ester
casted vessels. Arrow mark represents the middle cerebral artery vessel. Scale bar=500 μm.
C, Neuroscore was assessed daily and until 3 days after SAH. Data indicate mean±SEM. MCA
indicates middle cerebral artery; postC, post-conditioning; ROX-SE, 5-(and-6)-Carboxy-Xrhodamine, succinimidyl ester; SAH, subarachnoid hemorrhage; and WT, wild type. *P<0.05
sham vs SAH, **P<0.01 SAH vs SAH-post-conditioning, by ANOVA and Newman-Keuls multiple
comparison test, #P<0.05 SAH-post-conditioning vs SAH by 2-way repeated measures ANOVA
followed by Newman-Keuls multiple comparison test.

in sham group. Animals subjected to surgery were
found to have SAH at the time of animal euthanizing
and none in sham group were noted to have SAH.

Significant large artery vasospasm and neurological
deficits were noted in mice subjected to SAH (middle
cerebral artery diameter—63±17 μm) as compared
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Figure 3. Nitric oxide synthase inhibition blocks isoflurane conditioning-induced neurovascular protection against SAHinduced delayed cerebral ischemia.
A and B, Wild-type mice underwent SAH or sham surgery followed 1 hour later by exposure to 2% isoflurane or room air for 1 hour.
L-nitroarginine methyl ester 20 mg/kg was administered intraperitoneally before the surgery and every day after until the neurovascular
assessment. Vasospasm (A) was assessed on day 3. Neuroscore was assessed daily (B). Data indicate mean±SEM. A, *P<0.05
vs sham, (B) *P<0.05 vs sham by ANOVA and 2-way repeated measures ANOVA followed by Newman-Keuls multiple comparison
test. C and E, Endothelial nitric oxide synthase knockout mice underwent SAH or sham surgery followed 1 hour later by exposure
to 2% isoflurane or room air for 1 hour. Vasospasm (C) was assessed on day 3. Neuroscore was assessed daily (D). Data indicate
mean±SEM. C, *P<0.05 sham vs SAH, *P<0.05 sham vs SAH-post-conditioning by ANOVA and Newman-Keuls multiple comparison
test. D, Data indicate mean±SEM. *P<0.05 vs sham; #P<0.05 vs sham by 2-way repeated measures ANOVA followed by NewmanKeuls multiple comparison test. 3D: Representative images of 5-(and-6)-Carboxy-X-rhodamine, succinimidyl ester casted vessels.
Arrow mark represents the middle cerebral artery vessel. Scale bar=500 μm. eNOS indicates endothelial nitric oxide synthase; ISO,
isoflurane; KO, knockout mice; L-NAME, L-nitroarginine methyl ester; MCA, middle cerebral artery; NOS, nitric oxide synthase; postC,
post-conditioning; ROX-SE, 5-(and-6)-Carboxy-X-rhodamine, succinimidyl ester; and SAH, subarachnoid hemorrhage.

with sham surgery (91±31 μm) (P<0.05, Figure 2A
and 2C). Isoflurane conditioning was found to provide
strong protection against vasospasm (90±26 μm) and
led to an improvement in neurological scores after SAH
(P<0.05, Figure 2A through 2C).

L-NAME Administration Blocks IsofluraneInduced Neurovascular Protection Against
SAH
Next, we sought to determine if NOS is a critical
mediator of isoflurane induced neurovascular protection against SAH. Administration of the pan NOS
inhibitor, L-NAME, eliminated the isoflurane protection afforded against SAH-induced vasospasm
and neurological deficits in wild-type mice (P<0.05,
Figure 3A and 3B).

Isoflurane-Induced Neurovascular Protection
Against SAH is Lost in eNOS Null Mice
Out of 67 eNOS-null (eNOS−/−) mice used in the experiment, 1 animal (1%) died in the SAH group and none
died in sham group. All the animals subjected to surgery
were found to have SAH at the time of animal euthanizing, and none in sham group were noted to have SAH.
To directly implicate the role of eNOS in the isofluraneinduced neurovascular protection in SAH, eNOS-null
(eNOS−/−) mice were examined. Vasospasm and neurological deficits were seen in eNOS−/− mice subjected
to SAH (middle cerebral artery diameter—65±22 μm)
as compared with sham surgery (86±27 μm) (P<0.05,
Figure 3C and 3E), which is consistent with our past
findings.3 In contradistinction to the impact of isoflurane conditioning on SAH-induced vasospasm and
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neurological deficits in wild-type mice, exposure to isoflurane conditioning did not provide protection against
SAH-induced vasospasm (70±25 μm) or neurological
deficits in eNOS−/− mice (P<0.05, Figure 3C through 3E).

DISCUSSION
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The main findings of our study are as follows: (1) A
single exposure to 2% isoflurane for 1 hour increased
eNOS protein expression in naïve and SAH animals
at clinically relevant timepoints; (2) A single exposure
to 2% isoflurane for 1 hour initiated 1 hour after induction of SAH provided strong protection against
large artery vasospasm and neurological deficits
(consistent with our prior findings; Milner et al4); (3)
Pharmacological inhibition of NOS blocked isoflurane-induced neurovascular protection in SAH; and
(4) Global genetic knockout of eNOS blocked isoflurane-induced neurovascular protection in SAH. In
total, these findings indicate eNOS is a critical mediator of the neurovascular protection afforded by isoflurane conditioning in SAH.
Nitric oxide is a potent vasodilator, and reduced
nitric oxide is strongly implicated in DCI.7 eNOS—1
of the 3 known isoforms of NOS—is constitutively
expressed in endothelial cells throughout the body
including the central nervous system. It plays a key
role in the mediation of endothelial cell-dependent
vasodilation.8 While the effect of SAH on eNOS expression is controversial (some see no change 9; others see an increase10 or a decrease11), the concept
that eNOS upregulation is beneficial for DCI is widely
accepted.9,11 In the case of hypoxic conditioning for
SAH, eNOS has been strongly implicated as a key
mediator of the DCI protection afforded by this conditioning strategy.3 In the case of isoflurane conditioning, previous studies have implicated eNOS as a
critical mediator for isoflurane induced-cardiac protection5; however, the role of eNOS in isoflurane conditioning-induced protection of the central nervous
system has yet to be examined.
Evidence indicates that multiple anesthetics substantially augment expression levels of eNOS and
enhance the production of nitric oxide throughout the
body.12 In the central nervous system, inhalational anesthetics have been shown to markedly increase production of nitric oxide—a response that was blocked
by administration of the pan-NOS inhibitor, Nw-nitro-larginine.13 These findings are consistent with our results where we show isoflurane increases expression
of eNOS in the presence and absence of SAH, and
that both pharmacologic inhibition of NOS as well as
genetic inhibition of eNOS block the neurovascular
protection afforded by isoflurane conditioning in SAH.
These data strongly suggest eNOS and nitric oxide

Isoflurane Conditioning and eNOS in SAH

are key downstream effectors by which isoflurane
conditioning induces robust protection against SAHinduced DCI. Though others have suggested that the
neuronal NOS plays a role in isoflurane-induced cerebral hyperemia,14 the impact of the endothelial NOS
(eNOS) in isoflurane-induced protection against acute
brain injury (including SAH) has not been previously
elucidated. The results of the present study are therefore novel and impactful. When coupled with our previous finding that isoflurane conditioning-induced DCI
protection in SAH is dependent on endothelial cell-derived hypoxia inducible factor-1 alpha (a transcription
factor known to regulate eNOS expression15), results
from the present study suggest isoflurane conditioning
may be inducing a multistep cascade that ultimately
leads to the observed DCI and neurological protection.
Interestingly, we noted that L-NAME administration in SAH animals resulted in profound neurological deficits compared with the animals without
L-NAME administration. This observation suggests
other forms of NOS—namely inducible NOS and/
or neuronal NOS—likely play an important role in
SAH-induced neurological deficits. Additional experiments would be required to discern the specific
mechanisms, but several possibilities exist. Inhibition
of inducible NOS and/or neuronal NOS could further
exacerbate regional or even global nitric oxide levels
such that SAH-induced microcirculatory vasoconstriction is more pronounced leading to greater reductions in cerebral blood flow.
Our study has several limitations. First, though
the endovascular perforation mouse model used in
our study is well characterized and mimics many of
the features of SAH in humans, our findings will require validation in alternate animal models of SAH.
Second, our study focused solely on vasospasm-induced DCI and neurological deficits. Other contributors of DCI such as microcirculatory dysfunction
have been described, and the impact of isoflurane
conditioning on these non-vasospasm elements of
DCI will require additional study. Third, the impact of
isoflurane on longer-term end points such as neurobehavioral deficits after SAH were not evaluated,
which will be important before considering translational studies in humans. Finally, the dose of isoflurane used in our study is greater than that typically
used in patients, so additional studies to define optimal isoflurane dosing as well as a therapeutic window will be required.

CONCLUSIONS
We conclude that isoflurane provides significant protection against SAH-induced vasospasm and neurological deficits, and that eNOS is a critical mediator
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of this robust neurovascular protection. Given that
isoflurane is already approved by the Food and Drug
Administration for use in humans and has an excellent safety profile, the potential for translation to early
phase clinical trials is imminently feasible. Future studies further exploring the molecular underpinnings of
isoflurane conditioning-based neurovascular protection in experimental SAH are also warranted, with the
hopes of identifying druggable targets to be leveraged
into novel therapies.
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